AbbVie (ABBV) Highlights Additional Outcomes Data from Three Upadacitinib Phase 3 Studies in Rheumatoid Arthritis at EULAR 2018
Tweet Send to a Friend
AbbVie (NYSE: ABBV) today presented new patient-reported outcome data during the Annual European Congress of Rheumatology (EULAR 2018) in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
